Compare DexCom, Inc. (DXCM) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Texas Instruments Incorporated — how do they compare? DexCom, Inc. trades at $78.55 (market cap $28.06B), while Texas Instruments Incorporated trades at $291.03 (market cap $274.11B). The key difference: Texas Instruments Incorporated is far larger — about 9.8× DexCom, Inc.'s market cap, and Texas Instruments Incorporated pays a 1.89% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | TXN | |
|---|---|---|
Market Cap | $28.06B | $274.11B |
Sector | Health | Technology |
52-Week High | $89.53 | $332.35 |
52-Week Low | $54.84 | $153.33 |
Enterprise Value | $27.03B | $283.06B |
Dividend Yield | — | 1.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Texas Instruments (TXN) trades at $305.55, up 2.34% with a bullish technical signal. Recent Q1 2026 earnings beat expectations, with revenue growth to $17.68 billion in 2025. The company maintains strong profitability with 29.11% net margin and announced a CFO transition with Julie Knecht succeeding Rafael Lizardi in August 2026. Analysts show a buy consensus with a $317.20 price target, though valuation ratios like P/E of 52.23 appear elevated.
Outlook remains positive driven by AI data center demand and 300mm capacity expansion, but risks include high debt-to-asset ratio of 40.61% and competitive pressures. The stock presents growth potential with disciplined risk management advised given premium valuation and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
